ISSN:
1569-8041
Keywords:
Interleukin (IL)-10 mRNA
;
IL-10 receptor mRNA
;
non-small-cell lung cancer (NSCLC)
;
prognosis
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract Background:The type 2 cytokine interleukin (IL)-10 has beenreported to inhibit the antitumour activity of the regional immunity againstvarious neoplasms. Certain lung cancers produce IL-10, but the clinicalsignificance of IL-10 expression is not well understood. Patients and methods:We examined IL-10 and IL-10 receptor(IL-10R) mRNA expression in 82 non-small-cell lung cancers (NSCLC) by reversetranscription-polymerase chain reaction (RT–PCR) assay.Immunohistochemistry (IHC) and enzyme immunoassay (EIA) were applied toevaluate the cellular localisation and the serum levels of IL-10. Results:RT–PCR assay revealed IL-10 mRNA expression in 68(83%) of 82 NSCLC surgical specimens (40 of 50 adenocarcinomas, 22 of26 squamous cell carcinomas, 5 of 5 large-cell carcinomas, 1 of 1adenosquamous-cell carcinoma). RT–PCR assay also revealed IL-10R mRNAexpression in 79 cases of NSCLC (96.1%). IL-10 expression was confirmedwithin tumour cells by IHC. EIA showed no significant serum IL-10 elevationin the 12 NSCLC positive for IL-10 mRNA expression (0–2.99 pg/ml). TheNSCLC patients with IL-10 production showed significantly poorer prognosisthan those without IL-10 production (P 〈 0.05, Kaplan–Meier,log-rank test). Conclusions:These results suggested that the cytoplasmic IL-10correlated to clinical prognosis, and that IL-10 expression is a prognosticfactor for NSCLC.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1023/A:1008375208574
Permalink
